Results 221 to 230 of about 40,669 (305)

Investigation of Some Clinicopathologic Alterations in Cats Infected With Mycoplasma haemofelis and Candidatus Mycoplasma haemominutum in Mashhad, Iran: An Observational Cross‐Sectional Study

open access: yesVeterinary Medicine and Science, Volume 12, Issue 3, May 2026.
This study detected Mycoplasma haemofelis (34.78%) and Candidatus M. haemominutum (65.21%) in 23% of Iranian cats via PCR. Infection correlated with age, gender and outdoor access (*p < 0.05), causing significant hematologic/biochemical changes. No inter‐species differences in clinical presentation emerged between Mhf and CMhm. ABSTRACT Background Data
Esmaeel Shahtahmasbi   +3 more
wiley   +1 more source

Is a variant of uncertain significance always 'insignificant'? A systematic review on PRF1 A91V in Hemophagocytic Lymphohistocytosis and comparative analysis with Still's disease. [PDF]

open access: yesOrphanet J Rare Dis
Çakır İY   +14 more
europepmc   +1 more source

Cystic cervical thymoma in a cat

open access: yesVeterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract A 12‐year‐old, female, neutered Persian cat was presented with a 4‐month history of a progressively enlarging, soft, fluctuating, ventral cervical mass that intermittently caused dysphagia and coughing. Repeated aspiration temporarily reduced the swelling.
Rachel L. Nixon   +4 more
wiley   +1 more source

Integumentary fibrosarcoma in a free‐living swan (Cygnus olor): Medical and welfare considerations

open access: yesVeterinary Record Case Reports, Volume 14, Issue 2, May 2026.
Abstract A 10‐kg adult male mute swan (Cygnus olor) of unknown age was admitted for investigations of two large ventral masses overlying the keel bone, which were discharging purulent material. The masses measured 8.9 × 2.1 cm and 4.2 × 3.2 cm. Empirical treatment with non‐steroidal anti‐inflammatory drugs and antimicrobials was instigated.
Rachael Amy McKinney, Katherine Hughes
wiley   +1 more source

The Efficacy and Safety of Nab‐Paclitaxel Plus Anlotinib in Small‐Cell Lung Cancer for Second‐Line Therapy

open access: yesThoracic Cancer, Volume 17, Issue 9, May 2026.
Nab‐paclitaxel plus anlotinib significantly improved PFS, ORR, and OS with manageable safety in relapsed SCLC after first‐line chemoimmunotherapy, offering a promising second‐line therapeutic option. ABSTRACT Background Extensive Small‐cell lung cancer (ES‐SCLC) has a poor prognosis following the failure of first‐line therapy based immune checkpoint ...
Li‐Jun Tian   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos   +16 more
wiley   +1 more source

Concurrent Systemic Lupus Erythematosus and Hashimoto's Thyroiditis: Clinical Patterns From Two Cases in Southwestern Nigeria. [PDF]

open access: yesCase Rep Endocrinol
Odunlami GJ   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy